|Bid||73.22 x 900|
|Ask||73.34 x 1200|
|Day's Range||72.67 - 74.31|
|52 Week Range||68.44 - 91.40|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||26.49|
|Earnings Date||Feb. 02, 2022 - Feb. 07, 2022|
|Forward Dividend & Yield||2.60 (3.45%)|
|Ex-Dividend Date||Sep. 14, 2021|
|1y Target Est||93.21|
Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today it has entered into an agreement with Thermo Fisher Scientific to manufacture molnupiravir, Merck's investigational oral antiviral medicine for the treatment of COVID-19. This agreement is part of Merck's commitment to make this investigational medicine widely available globally, if approved for use by regulatory agencies. Molnupiravir is being developed by Merck in collaboration with Ridgeback Biotherapeutics.
We are proud to support the Hiring Our Heroes Corporate Fellowship Program, bringing fantastic members to our team! Learn more about our support for veterans here: http://bit.ly/3lF5iQR
Bristol Myers' (BMY) sBLA seeking label expansion of Reblozyl for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia gets priority review by the FDA.